

Ursula Creutzig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7202865/publications.pdf>

Version: 2024-02-01

93
papers

5,659
citations

76031

42
h-index

90395

73
g-index

97
all docs

97
docs citations

97
times ranked

5156
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29341.	0.8	5
2	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Cancers</i> , 2021, 13, 789.	1.7	10
3	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	1.7	30
4	Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). <i>Klinische Padiatrie</i> , 2021, 233, 267-277.	0.2	4
5	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	3.3	19
6	Early deaths from childhood cancer in Germany 1980-2016. <i>Cancer Epidemiology</i> , 2020, 65, 101669.	0.8	5
7	Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome. <i>Blood</i> , 2020, 136, 6-7.	0.6	1
8	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Blood</i> , 2020, 136, 24-24.	0.6	0
9	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. <i>Haematologica</i> , 2019, 104, 120-127.	1.7	38
10	Mutated <i>WT1</i> , <i>FLT3-ITD</i> , and <i>NUP98-NSD1</i> Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	0.6	48
11	Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study. <i>Neuro-Oncology</i> , 2019, 21, 1069-1081.	0.6	16
12	Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. <i>Leukemia</i> , 2018, 32, 2167-2177.	3.3	155
13	Acute myelogenous leukemia in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27089.	0.8	50
14	Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. <i>Blood Advances</i> , 2018, 2, 1532-1540.	2.5	36
15	First experience of the AML—Berlin—Frankfurt—Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26461.	0.8	32
16	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.	0.6	64
17	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	0.8	14
18	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Acute Myelogenous Leukemia. <i>Pediatric Oncology</i> , 2017, , 135-149.	0.5	0
20	Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1070-1074.	0.8	19
21	Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1677-1679.	0.8	18
22	Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. <i>Pediatric Blood and Cancer</i> , 2016, 63, 640-645.	0.8	28
23	Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. <i>British Journal of Haematology</i> , 2016, 175, 588-601.	1.2	14
24	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. <i>Cancer</i> , 2016, 122, 3821-3830.	2.0	92
25	Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1457-1460.	0.8	14
26	Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2776-2783.	0.8	48
27	Gemtuzumab in Children with Relapsed and Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis: A Report of the AML-BFM Study Group. <i>Blood</i> , 2016, 128, 1637-1637.	0.6	2
28	The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study. <i>Blood</i> , 2016, 128, 2896-2896.	0.6	1
29	Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012. <i>Blood</i> , 2016, 128, 450-450.	0.6	3
30	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	0.6	69
31	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.	0.8	54
32	Clinical Impact of Additional Cytogenetic Aberrations, <i>ckit</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	0.8	75
33	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	0.8	277
34	Gene Expression Profiles Associated with Pediatric Relapsed AML. <i>PLoS ONE</i> , 2015, 10, e0121730.	1.1	22
35	Glucocorticoid-Induced Proliferation and Lack of Differentiation in Untreated Pediatric Acute Myeloid Leukemic Blasts. <i>Blood</i> , 2015, 126, 4843-4843.	0.6	0
36	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. <i>Blood</i> , 2015, 126, 172-172.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Exchange Transfusion and Leukapheresis in Pediatric AML Patients with High Risk of Early Death for Bleeding and Leukostasis. <i>Blood</i> , 2015, 126, 3741-3741.	0.6	0
38	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. <i>Haematologica</i> , 2014, 99, 1472-1478.	1.7	42
39	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. <i>British Journal of Haematology</i> , 2014, 166, 902-910.	1.2	22
40	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	0.6	0
41	Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 5-8.	0.3	3
42	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. <i>Blood</i> , 2013, 122, 37-43.	0.6	151
43	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 599-607.	0.8	197
44	Pediatric Fanconi Anemia With Secondary AML: A Retrospective Outcome Report From The German AML-BFM Group. <i>Blood</i> , 2013, 122, 1414-1414.	0.6	1
45	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.	1.7	78
46	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	0.6	451
47	Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). <i>Annals of Hematology</i> , 2012, 91, 9-18.	0.8	73
48	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2012, 120, 888-888.	0.6	3
49	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	0.6	58
50	NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. <i>Blood</i> , 2011, 118, 3645-3656.	0.6	250
51	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). <i>Blood</i> , 2011, 118, 5409-5415.	0.6	56
52	CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. <i>Pediatric Blood and Cancer</i> , 2011, 57, 986-992.	0.8	25
53	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1478-1487.	1.7	102
54	Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. <i>Archives of Disease in Childhood</i> , 2011, 96, 1026-1032.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells. <i>Blood</i> , 2011, 118, 4873-4873.	0.6	0
56	A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2205-2214.	0.6	120
57	High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. <i>Blood</i> , 2010, 116, 2752-2758.	0.6	71
58	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. <i>British Journal of Haematology</i> , 2010, 148, 768-776.	1.2	75
59	Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. <i>British Journal of Haematology</i> , 2010, 149, 84-92.	1.2	92
60	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. <i>British Journal of Haematology</i> , 2010, 149, 399-409.	1.2	52
61	Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2010, 28, 2682-2689.	0.8	190
62	Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective <i>G-CSF</i> Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 2591-2597.	0.8	62
63	Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1075-1075.	0.6	3
64	Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity. <i>Blood</i> , 2010, 116, 181-181.	0.6	13
65	Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation. <i>Blood</i> , 2010, 116, 3243-3243.	0.6	0
66	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. <i>Blood</i> , 2010, 116, 762-762.	0.6	2
67	Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004. <i>Blood</i> , 2010, 116, 17-17.	0.6	4
68	New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004. <i>Blood</i> , 2010, 116, 2741-2741.	0.6	0
69	WT1 Expression at the Diagnosis of Childhood AML Has No Prognostic Value but Corresponds with the Biological Characteristics of Leukemic Cells - Results From European Multicenter Study.. <i>Blood</i> , 2010, 116, 1684-1684.	0.6	0
70	Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 159-172.	1.0	2
71	Imperative of continual support by the European Community for future advances in paediatric oncology in Europe: meeting report of the EC-funded science-communication project DIRECT – ‘Overcoming Cancer with Research’. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 234-245.	0.3	3
72	More and better cure for an orphan: priorities for future paediatric cancer research in Europe – Meeting report of the EC-funded science-communication project DIRECT – ‘Overcoming Cancer with Research’. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 246-254.	0.3	0

#	ARTICLE	IF	CITATIONS
73	International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 125-128.	1.2	69
74	Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. <i>Blood</i> , 2009, 113, 5951-5960.	0.6	112
75	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	0.6	383
76	Significance of age in acute myeloid leukemia patients younger than 30 years. <i>Cancer</i> , 2008, 112, 562-571.	2.0	91
77	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 826-833.	1.7	64
78	Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. <i>Blood</i> , 2008, 111, 2899-2903.	0.6	9
79	Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. <i>Blood</i> , 2008, 111, 2991-2998.	0.6	228
80	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. <i>Blood</i> , 2007, 109, 4641-4647.	0.6	126
81	Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. <i>Blood</i> , 2007, 109, 936-943.	0.6	52
82	Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. <i>Pediatric Blood and Cancer</i> , 2007, 48, 651-662.	0.8	83
83	Relapsed acute myeloid leukemia. , 2006, , 540-547.		0
84	Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3686-3692.	0.8	132
85	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2006, 24, 4499-4506.	0.8	173
86	Long Term Data on Anthracycline Cardiotoxicity in 547 Children with AML.. <i>Blood</i> , 2006, 108, 2014-2014.	0.6	0
87	Quality Management for Clinical Trials within the German Competence Network Paediatric Oncology and Haematology. <i>Oncology Research and Treatment</i> , 2005, 28, 333-336.	0.8	4
88	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2004, 22, 4384-4393.	0.8	230
89	Impact of Granulocyte Colony-Stimulating Factor during Induction Therapy in Children with Acute Myelogenous Leukemia: Results from the Prospective and Randomized Trial AML-BFM 98.. <i>Blood</i> , 2004, 104, 2911-2911.	0.6	2
90	Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. <i>Blood</i> , 2003, 101, 3868-3871.	0.6	94

#	ARTICLE	IF	CITATIONS
91	Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. <i>Blood</i> , 2002, 99, 245-251.	0.6	153
92	Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. , 1996, 26, 397-404.		26
93	Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. <i>Cancer</i> , 1987, 60, 3071-3079.	2.0	112